Phaseline

Targets › SLAMF7

SLAMF7 (SLAM family member 7): drug programs, companies and trials

10 programs from 9 companies in 11 trials: 5 Phase 2, 4 Phase 1, 2 Phase 3; Oncology; next expected readout Dec 2026.

Self-ligand receptor of the signaling lymphocytic activation molecule (SLAM) family. SLAM receptors triggered by homo- or heterotypic cell-cell interactions are modulating the activation and differentiation of a wide variety of immune cells and thus are involved in the regulation and interconnection of both innate and adaptive immune response. (UniProt, Q9NQ25)

Open in Phaseline: the race on SLAMF7, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
European Myeloma Network B.V.Elotuzumab
SLAM family member 7 inhibitor
SLAMF7Phase 3Multiple MyelomaMar 2029
Wuerzburg University HospitalElotuzumab
SLAM family member 7 inhibitor
SLAMF7Phase 3Newly Diagnosed Multiple MyelomaAug 2029
Massachusetts General HospitalElotuzumab
SLAM family member 7 inhibitor
SLAMF7Phase 2Multiple MyelomaDec 2026
Medical College of WisconsinElotuzumab
SLAM family member 7 inhibitor
SLAMF7Phase 2Multiple MyelomaApr 2027
M.D. Anderson Cancer CenterElotuzumab
SLAM family member 7 inhibitor
SLAMF7Phase 2Hematopoietic Cell Transplantation Recipient; Myelofibrosis Transformation in Essential ThrombocythemiaApr 2027
Washington University School of MedicineElotuzumab
SLAM family member 7 inhibitor
SLAMF7Phase 2Multiple Myeloma in RelapseSep 2027
Yale UniversityElotuzumab
SLAM family member 7 inhibitor
SLAMF7Phase 1Multiple MyelomaDec 2026
Abdullah KhanElotuzumab
SLAM family member 7 inhibitor
SLAMF7Phase 1Recurrent Multiple MyelomaDec 2026
Washington University School of MedicineWS-CART-CS1
SLAMF7-targeting CAR-T cell therapy
SLAMF7Phase 1Multiple MyelomaAug 2029
Omar Nadeem, MDElotuzumab
SLAM family member 7 inhibitor
SLAMF7Phase 1MyelomaDec 2029

Conditions

Multiple Myeloma (5) Hematopoietic Cell Transplantation Recipient (1) Myelofibrosis Transformation in Essential Thrombocythemia (1) Multiple Myeloma in Relapse (1) Newly Diagnosed Multiple Myeloma (1) Myeloma (1) Recurrent Multiple Myeloma (1)

Modalities

mixed (8), antibody (1), other (1)

Companies

Washington University School of Medicine (2) M.D. Anderson Cancer Center (1) Medical College of Wisconsin (1) Yale University (1) Wuerzburg University Hospital (1) Massachusetts General Hospital (1) Omar Nadeem, MD (1) European Myeloma Network B.V. (1) Abdullah Khan (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.